The National Institute for Health and Clinical Excellence, or NICE, said Wednesday it has rejected GlaxoSmithKline PLC's (GSK) oral Tyverb (lapatinib) in combination with capecitabine for the treatment of an aggressive form of advanced breast cancer, despite complying with the new NICE guidance on treatments for small patient populations with a short life expectancy.

MAIN FACTS:

-Decision to deny NHS patients access to treatment with lapatinib follows the request in July by NICE’s Appeal Panel that the Appraisal Committee should re-consider lapatinib under the Institute’s end of life (EOL) supplementary guidance.

-Final guidance is expected later in the year.

-GSK submitted additional data demonstrating that lapatinib met all three of the EOL criteria but NICE felt lapatinib was still not a cost-effective use of NHS resources.

-Decision made despite GSK offering the Tyverb Patient Access Programme, which allows NHS patients in the U.K. free access to lapatinib for the first three months of treatment.

-Tyverb is a registered trademark of the GlaxoSmithKline group of companies

 
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.